Jazz Pharmaceuticals plc Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement
Jazz Pharmaceuticals plc (JAZZ) had Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement of $1.90 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Offsetting
us-gaap:DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement · last filed 2026-08-03
- 2026-06-30: Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement $1.90M.
- 2026-03-31: Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement $0.00.
- 2025-12-31: Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement $6.30M; Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement as first filed $6.26M.
- 2025-09-30: Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement $1.72M.
| Period end | Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement | Derivative Asset, Fair Value, Gross Asset Including Not Subject to Master Netting Arrangement as first filed |
|---|---|---|
| 2026-06-30 | $1.90M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $6.30M 10-Q · filed 2026-08-03 | $6.26M 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.72M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $9.14M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $6.85M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $3.24M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $8.38M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $6.71M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $6.17M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $21.82M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $10.91M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $8.69M 10-Q · filed 2023-08-09 | |
| 2022-12-31 | $17.36M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $580.00K 10-K · filed 2023-03-01 | |
| 2021-09-30 | $1.20M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $1.35M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $488.00K 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $11.91M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $4.08M 10-Q · filed 2020-11-02 | |
| 2020-06-30 | $1.45M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $316.00K 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $2.51M 10-K · filed 2021-02-23 | |
| 2019-09-30 | $1.01M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $1.75M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $2.30M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $5.26M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $8.09M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $7.08M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $6.32M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $17.63M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $12.32M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $9.01M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $1.67M 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |